Pharmacology Chapter 7 Drugs Affecting Nicotinic Receptors

The only therapeutic use of _______ is as an adjunct in tobacco cessation programs.

nicotine

________ is a partial agonist at nicotinic receptors

Varenicline

Used for smoking cessation

All 3 are ganglionic blockers what are their type

Nicotine

Trimethaphan

Hexamethonium

Depolarizing drugs

Competitive drug interfere with binding of ACh

Noncompetitive

All nondepolarizing or competitive neuromuscular blocking drug contain at least one quaternary ______

nitrogen

What is d-tubocurarine

What is succinylcholine

Depolarizing Neuromuscular blocking drug (agonist but is slowly broken down)

Nondepoalrizing Neuromuscular blocking drug (competitive blockers)

Both are muscle relaxer

Work on nicotinic receptor

Do neuromuscular blocker affect CNS

No

Several neuromuscular blocking agents, most prominently tubocurarine, cause the release of _______ from mast cells into the circulation

histamine

Can cause hypotension, edema, and vasodialtion

The major risk of overdosage with neuromuscular blocking agents is death from _______ failure

respiratory

Paralysis from _______ agents may be reversed to some extent through administration of an anticholinesterase (e.g., neostigmine), generally accompanied by an antimuscarinic drug (e.g., atropine) to prevent excessive muscarinic receptor-mediated sequelae to the anticholinesterase.

nondepolarizing

_______, a _______ compound, facilitates inhibition of γ-aminobutyric acid (GABA) in the CNS can be used to relax muscle and treat anxiety

Diazepam. benzodiazepine

_______ is an orally effective agonist for the presynaptic CNS GABAB (metabotropic) receptor.

Baclofen

Another muscle relaxer

_______ is a clonidine-like α2-adrenoceptor stimulant that reduces skeletal muscle spasticity by a CNS inhibitory action, but with less hypotension than seen with clonidine.

Tizanidine

________ is structurally and mechanistically related to the tricyclic antidepressants. It is used for short-term (1 to 2 weeks) treatment of muscular spasms associated with musculoskeletal conditions including temporomandibular joint (TMJ) disorders.

Cyclobenzaprine

The toxin produced by _______ _______ acts on the motor nerve terminal to prevent the release of ACh in response to the arrival of an axonal action potential

Clostridium botulinum

________ is an agent that acts within the skeletal muscle fiber rather than on the neuromuscular junction

Dantrolene

What drugs are to reduce contraction of skeletal muscle in TMJ disorders

Cyclobenzaprine and diazepam